CTVA vs LQDA
CTVA: Corteva is a global agriculture leader specializing in advanced seed technology and crop protection solutions to support sustainable farming. LQDA: A biopharmaceutical company revolutionizing treatment for pulmonary hypertension using its proprietary PRINT particle engineering technology and treprostinil-based therapies.
Side-by-side fundamentals
| Metric | CTVA | LQDA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $13.75 | $28.02 | |
| Market cap | $9.2B | $2.5B | |
| P/E as of 2026-10-08 | 9.09 | 171.80 | CTVA lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 21.63 | n/a | |
| Net margin FY2025, SEC XBRL | +6.3% | -43.5% | CTVA higher |
| Operating margin FY2025, SEC XBRL | n/a | -32.5% | |
| ROE FY2025, SEC XBRL | +4.5% | -154.0% | CTVA higher |
| ROA FY2025, SEC XBRL | +2.6% | -21.0% | CTVA higher |
| Debt / equity as of 2026-09-03 | 0.19 | 1.64 | CTVA lower |
| Revenue growth (YoY) as of 2026-09-03 | +3.7% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.1% | +115.0% | LQDA higher |
| Dividend yield as of 2026-09-03 | +0.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 7 | 0 | CTVA higher |
| Beta as of 2026-09-03 | 0.51 | 1.00 | |
| 1-year return as of 2026-10-08 close | -78.2% | +16.4% | LQDA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.